Literature DB >> 33175240

Liver tumor F-18 FDG-PET before and immediately after microwave ablation enables imaging and quantification of tumor tissue contraction.

Zihao Yan1,2, Ramin Khorasani1,2,3, Vincent M Levesque3, Victor H Gerbaudo1,3, Paul B Shyn4,5.   

Abstract

PURPOSE: Poor liver tumor visibility after microwave ablation (MWA) limits direct tumor ablation margin assessments using contrast-enhanced CT or ultrasound (US). Positron emission tomography (PET) or PET/CT may offer improved intraprocedural assessment of liver tumor ablation margins versus current imaging techniques, as 18F-fluorodeoxyglucose (18F-FDG)-avid tumors remain visible on PET immediately following ablation. The purpose of this study was to assess intraprocedural 18F-FDG PET scans before and immediately after PET/CT-guided MWA for visualization and quantification of metabolic liver tumor tissue contraction resulting from MWA.
METHODS: This retrospective study, conducted at a large academic medical center after Institutional Review Board approval, included 36 patients (20 men; mean age 63 [range 37-85]) who underwent PET/CT-guided MWA of 42 18F-FDG-avid liver tumors from May 2013 to March 2018. Tumor metabolic diameters (short/long axes) were measured for each tumor on pre- and post-ablation PET images. Tumor metabolic volumes were calculated using tumor diameter measurements and compared with automated volumes using an SUV threshold algorithm. A two-tailed paired t test was used for the analyses.
RESULTS: Comparing intraprocedural pre- and post-ablation PET images, mean metabolic tumor short- and long-axis diameters decreased from 21.4 to 14.9 mm [- 29%, p < 0.001, standard deviation (SD) 18%] and from 24.0 to 18.0 mm (- 24%, p < 0.001, SD 16%), respectively. The mean calculated tumor metabolic volume decreased from 10.5 to 4.6 mm3 (- 55%, p < 0.001, SD 26%). The mean automated tumor metabolic volume decreased from 10.6 to 5.8 mm3 (- 45%, p < 0.001, SD 30%).
CONCLUSION: Intraprocedural PET images of 18F-FDG-avid liver tumors allow visualization and quantification of MWA-induced metabolic tumor tissue contraction during 18F-FDG PET/CT-guided procedures. The ability to visualize contracted tumor immediately post-MWA may facilitate emerging intraprocedural PET and PET/CT imaging techniques that address a clinical gap in directly assessing the ablation margin.

Entities:  

Keywords:  Interventional oncology; Liver tumor ablation; PET/CT; Tissue contraction; Tumor ablation margin

Mesh:

Substances:

Year:  2020        PMID: 33175240     DOI: 10.1007/s00259-020-05104-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  3 in total

1.  SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.

Authors:  Sylvain Beaulieu; Paul Kinahan; Jeffrey Tseng; Lisa K Dunnwald; Erin K Schubert; Pam Pham; Barbara Lewellen; David A Mankoff
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

2.  Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results.

Authors:  Guido Poggi; Benedetta Montagna; Pamela DI Cesare; Giulia Riva; Giovanni Bernardo; Mauro Mazzucco; Alberto Riccardi
Journal:  Anticancer Res       Date:  2013-03       Impact factor: 2.480

Review 3.  Minimally invasive local therapies for liver cancer.

Authors:  David Li; Josephine Kang; Benjamin J Golas; Vincent W Yeung; David C Madoff
Journal:  Cancer Biol Med       Date:  2014-12       Impact factor: 4.248

  3 in total
  2 in total

1.  An activated excretion-retarded tumor imaging strategy towards metabolic organs.

Authors:  Da-Yong Hou; Man-Di Wang; Xing-Jie Hu; Zhi-Jia Wang; Ni-Yuan Zhang; Gan-Tian Lv; Jia-Qi Wang; Xiu-Hai Wu; Lu Wang; Hao Wang; Wanhai Xu
Journal:  Bioact Mater       Date:  2021-12-17

2.  A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation.

Authors:  Brett Z Fite; James Wang; Pejman Ghanouni; Katherine W Ferrara
Journal:  BME Front       Date:  2022-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.